more news, click here
- Join us at the 3rd Nordic Neuroscience Meeting in Helsinki, Finland. For more info, please click here.
- Join us at the 5th World Parkinson congress in Kyoto, Japan. For more info, please click here.
- Docent Laurent Roybon gives inspirational lecture at the 2nd Nordic PhD summit, at the University of Helsinki, in Finland. The meeting was organized by PhD students from Nordic Universities, and under the theme "Think Open". For more information, please see Nordoc website.
- New study published in PNAS reveals developmental changes in Huntington's disease, raising the possibility that like Huntington's disease, neurodegenerative diseases Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis may be neurodevelopmental diseases, if inherited. The study is led by Prof. Stephan Von Hörsten.
- BAGADILICO final event took place at Ystad Saltsjöbad. Dr. Kaspar Russ and PhD students Carla Azevedo and Margarita Chumarina presented posters during the event, which was finalized by an empowering lecture by Patrik Brundin, founder of BAGADILICO, now Director of the Center for Neurodegenerative Science at the Jay Van Andel Research Institute in Grand Rapids, USA.
- PhD student Carla Azevedo awarded best poster at the Neuroscience day in Lund: The Segerfalk Foundation generously awarded 8,000 SEK to Carla for travel to conference. Congratulation Carla!
- CSC awarded a new grant from the MJFF! Great support can only lead to great discoveries with major impact for patients.
Research in the laboratory attempts to define pathogenic cellular and molecular mechanisms involved in synucleiopathies, in particular Parkinson's disease and multiple system atrophy, and Alzheimer's disease. To this aim, we generate induced pluripotent stem cells (iPSC) from patients, which we utilize to understand cell autonomous and non-cell autonomous processes that lead to neuronal damage.
By generating iPSCs from patients suffering familial and idiopathic forms of the diseases, we aim to elucidate causative mechanisms leading to neural cell dysfunction, and neurodegeneration.
Our cutting-edge approach will allow for the identification of new molecular targets, which could be used for the development of new diagnostic tools for early diagnosis, as well as for the stratification and recruitment of patients for future clinical trials.